Tag: Pancreatic ductal adenocarcinoma

Recent advancements in oncology have unveiled a pressing need to explore the intricacies of immune checkpoint inhibitors, particularly focusing on ...

Peptidyl-arginine deiminase 2 (PAD2) has emerged as a pivotal enzyme driving the progression of pancreatic ductal adenocarcinoma (PDAC), one of ...

Pancreatic cancer remains a formidable adversary in the realm of oncology, characterized by its stealthy progression and dire prognosis. Among ...